Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lineage Cell Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
LCTX
American
8731
https://lineagecell.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lineage Cell Therapeutics Inc
12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By
- Apr 19th, 2024 4:13 pm
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
- Apr 1st, 2024 12:00 pm
15 Best Anti-Aging Foods for Youthful Skin
- Mar 18th, 2024 2:31 pm
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
- Mar 18th, 2024 12:00 pm
Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks
- Mar 14th, 2024 7:53 pm
RG6501 (OpRegenĀ®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
- Mar 13th, 2024 12:00 pm
RG6501 (OpRegenĀ®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
- Mar 11th, 2024 12:00 pm
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript
- Mar 8th, 2024 9:20 pm
Lineage Cell Therapeutics Inc. Reports Q4 and Full Year 2023 Financial Results
- Mar 8th, 2024 3:36 am
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 7th, 2024 9:01 pm
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
- Feb 29th, 2024 1:00 pm
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
- Feb 13th, 2024 1:00 pm
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
- Feb 9th, 2024 2:15 pm
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
- Feb 6th, 2024 2:15 pm
RG6501 (OpRegenĀ®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
- Jan 16th, 2024 1:00 pm
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
- Dec 18th, 2023 1:00 pm
3 Penny Stocks to Buy for the Next Bull Run
- Nov 11th, 2023 9:02 pm
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript
- Nov 10th, 2023 7:13 pm
Q3 2023 Lineage Cell Therapeutics Inc Earnings Call
- Nov 10th, 2023 2:17 pm
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 9th, 2023 9:01 pm
Scroll